# Geekgene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/geekgene

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.geekgene.com.cn
- Latest round: Angel (Mar 15, 2021)
- Investors on record: 1

## About

Established in 2021 and based in Suzhou, China, Geekgene is an innovative cellular drug development company featuring high-throughput genomic data to modulate cell fate, with a core team from Peking University and Harvard University. The company is a national high-tech enterprise, co-founded by Dr. Jun Yong and Dr. Weifeng Lai. In June 2025, Geekgene raised CNY 30 million in venture funding from new investor BrightGene Bio-Medical Technology Co., Ltd. and returning investor Qihang Capital.
The company mainly develops genetic drugs, focusing on the preparation of T cells for the treatment of mid- to late-stage solid tumors. We also provide development, service and application of sequencing technology for single cells and small amount of cells, such as single cell whole genome sequencing, single cell transcriptome sequencing and single cell epigenetic study.
The company’s revenue is generated by providing single cell sequencing services, bioinformatics analysis, and licensing of cell therapy technologies to biotechnology and pharmaceutical clients.

## Funding rounds

- Angel, Mar 15, 2021 — Guoqian Venture Capital

## Investors

- Guoqian Venture Capital (https://capitalatlas.ai/funds/guoqian-venture-capital) — Angel